Fibryga (Human Fibrinogen)
Plasma-derived coagulation factor for fibrinogen deficiency
Quick Facts About Fibryga
Key Takeaways
- Fibryga is a purified human fibrinogen concentrate derived from pooled human plasma, used to replace deficient fibrinogen (coagulation factor I) in patients with congenital or acquired deficiency.
- It is administered exclusively by intravenous infusion in hospital settings by trained healthcare professionals, with dosing individualized based on body weight and target fibrinogen levels.
- Important risks include thromboembolic events (blood clots), allergic or anaphylactic reactions, and a theoretical risk of transmitting infectious agents from human plasma.
- The reconstituted solution should be used immediately for microbiological safety, though stability has been demonstrated for up to 24 hours at room temperature (max 25 °C).
- Fibryga is approved across the European Economic Area and is also marketed as Fibrema in Slovenia.
What Is Fibryga and What Is It Used For?
Quick Answer: Fibryga is a prescription medicine containing human fibrinogen, an essential blood clotting protein. It is used to treat and prevent bleeding in patients whose blood does not clot properly due to a fibrinogen deficiency, whether inherited (congenital) or developed during surgery or critical illness (acquired).
Fibrinogen, also known as coagulation factor I, is a glycoprotein produced by the liver that plays a central role in the blood coagulation cascade. When a blood vessel is injured, a complex series of enzymatic reactions are triggered. At the final stage, the enzyme thrombin converts soluble fibrinogen into insoluble fibrin strands. These fibrin strands polymerize and are cross-linked by factor XIII to form a stable mesh that constitutes the structural framework of a blood clot. Without adequate fibrinogen, this process is impaired, leading to excessive or uncontrolled bleeding.
Fibryga provides purified human fibrinogen derived from pooled human plasma donations. It is manufactured by Octapharma using a proprietary purification and viral inactivation process. Each vial contains 1 gram of fibrinogen as a lyophilized (freeze-dried) powder, which is reconstituted with 50 ml of water for injection before intravenous administration, yielding a concentration of 20 mg/ml.
Congenital Fibrinogen Deficiency
Congenital fibrinogen disorders are rare inherited conditions affecting approximately 1 in 1,000,000 people worldwide. They include afibrinogenemia (complete absence of fibrinogen), hypofibrinogenemia (reduced fibrinogen levels), and dysfibrinogenemia (functionally abnormal fibrinogen). Patients with these conditions may experience spontaneous bleeding episodes, prolonged bleeding after trauma or surgery, and complications during pregnancy. Fibryga is indicated for the treatment of acute bleeding episodes and for prophylactic use before and during surgical procedures to maintain adequate hemostasis.
Acquired Fibrinogen Deficiency
Acquired fibrinogen deficiency occurs when fibrinogen is consumed faster than the body can produce it. This can happen during major surgical procedures, massive hemorrhage, disseminated intravascular coagulation (DIC), severe liver disease, or obstetric complications. In these critical situations, rapid fibrinogen replacement may be life-saving. Fibryga is indicated for the replacement of fibrinogen in adult patients with uncontrolled severe bleeding and acquired fibrinogen deficiency during surgical interventions.
In clinical practice, fibrinogen concentrate such as Fibryga offers several advantages over cryoprecipitate (another source of fibrinogen): standardized fibrinogen content per vial, reduced volume of infusion, no need for blood group matching, lower risk of transfusion-related complications, and rapid availability without the need for thawing. The International Society on Thrombosis and Haemostasis (ISTH) and other expert guidelines increasingly support the use of fibrinogen concentrates as a first-line therapy for fibrinogen replacement in critical bleeding scenarios.
What Should You Know Before Taking Fibryga?
Quick Answer: Do not use Fibryga if you are allergic to human fibrinogen or any of its other ingredients. Your doctor must weigh the benefits against the risk of blood clots, especially if you have cardiovascular disease, liver disease, are undergoing or recovering from surgery, or are a newborn.
Contraindications
Fibryga must not be used in patients who have a known allergy (hypersensitivity) to human fibrinogen or to any of the excipients contained in the product. These excipients include L-arginine hydrochloride, glycine, sodium chloride, and sodium citrate dihydrate. If you have previously experienced an allergic reaction to Fibryga or any other fibrinogen product, inform your doctor before receiving this medication. Your physician will assess whether the potential benefit of treatment outweighs the risk and may administer prophylactic antiallergic medication if treatment is deemed necessary.
Warnings and Precautions
There is a risk of blood clot formation (thromboembolism) when using fibrinogen concentrate, particularly with high or repeated doses. Your doctor will carefully evaluate the balance between the benefits of treatment and the risk of thromboembolic complications. This risk is heightened in patients with a history of coronary artery disease or myocardial infarction, liver disease, those in the perioperative period (before, during, or after surgery), neonates, and patients at risk for thromboembolic events or disseminated intravascular coagulation (DIC). Monitoring with coagulation tests will be performed to assess your risk.
As with all plasma-derived protein products administered intravenously, allergic or anaphylactic reactions may occur. Be vigilant for early signs of hypersensitivity including hives (urticaria), skin rash, chest tightness, wheezing, low blood pressure (hypotension), and anaphylaxis. If any of these symptoms occur, the infusion must be stopped immediately and appropriate emergency treatment initiated. Your healthcare team will have emergency medications readily available.
Fibryga is derived from human plasma, and despite rigorous donor screening and viral inactivation steps during manufacturing, the risk of transmitting infectious agents cannot be entirely eliminated. The manufacturing process includes measures effective against enveloped viruses such as HIV, hepatitis B, and hepatitis C, as well as the non-enveloped hepatitis A virus. However, measures may be of limited value against non-enveloped viruses such as parvovirus B19. Parvovirus B19 infection may be serious for pregnant women (risk to the fetus) and for immunocompromised individuals or those with certain types of anemia (such as sickle cell disease). Your doctor may recommend hepatitis A and B vaccination if you regularly receive plasma-derived fibrinogen products.
It is strongly recommended that the product name and batch number be recorded each time Fibryga is administered, in order to maintain traceability of the batches used. This is important for pharmacovigilance and the ability to trace any potential safety signals back to specific plasma pools.
Children and Adolescents
There are no specific additional warnings or precautions for children and adolescents beyond those applicable to adult patients. However, the dosing formula differs for children under 12 years of age (see the Dosage section). Clinical data in the pediatric population are more limited than in adults, and treatment should be supervised by a physician experienced in the management of coagulation disorders.
Pregnancy and Breastfeeding
The safety of Fibryga during pregnancy and breastfeeding has not been established in controlled clinical trials. Animal reproduction studies have not been conducted with Fibryga. Fibryga should only be used during pregnancy or while breastfeeding if clearly indicated by a healthcare professional, and only when the potential benefit justifies the potential risk to the mother and fetus or infant. It is important to note that parvovirus B19 infection, which carries a theoretical transmission risk with plasma-derived products, can be particularly harmful during pregnancy as it may cause fetal hydrops or miscarriage.
Driving and Operating Machinery
Fibryga has no or negligible effect on the ability to drive or operate machinery. However, given that this medication is administered in clinical settings for serious bleeding conditions, driving is unlikely to be an immediate consideration following treatment.
Sodium Content
Fibryga contains up to 132 mg of sodium per vial, equivalent to approximately 6.6% of the WHO-recommended maximum daily intake of 2 g sodium for an adult. This should be taken into account for patients on a sodium-restricted diet, particularly if multiple vials are administered.
How Does Fibryga Interact with Other Drugs?
Quick Answer: Fibryga must not be mixed with other medicinal products. No specific drug-drug interaction studies have been conducted, but concurrent use with other procoagulant agents may increase the risk of thrombosis. Always inform your healthcare team about all medications you are using.
No formal drug interaction studies have been conducted with Fibryga. However, based on its mechanism of action as a coagulation factor replacement, certain pharmacological considerations apply. Fibryga provides fibrinogen, which is the substrate for thrombin in the final common pathway of the coagulation cascade. Drugs or products that enhance coagulation may have additive effects when used concurrently, potentially increasing the risk of thromboembolic events.
Fibryga must not be mixed with other medicinal products in the same syringe or infusion line, except as specified in the reconstitution instructions. This is a critical safety requirement, as incompatibilities with other solutions could affect the integrity and efficacy of the fibrinogen protein or cause adverse reactions.
| Drug / Drug Class | Interaction Type | Clinical Significance | Recommendation |
|---|---|---|---|
| Prothrombin complex concentrates (PCCs) | Additive procoagulant effect | Increased risk of thrombosis | Monitor closely; use lowest effective dose |
| Tranexamic acid (antifibrinolytic) | Reduced fibrin clot breakdown | Potential increased thrombotic risk | Balance hemostatic benefit vs. thrombotic risk |
| Factor XIII concentrate | Enhanced clot stabilization | May increase thrombotic risk | Monitor coagulation parameters |
| Recombinant factor VIIa (rFVIIa) | Enhanced thrombin generation | Significantly increased thrombotic risk | Use combination with extreme caution |
| Anticoagulants (heparin, warfarin) | Opposing pharmacological effect | May reduce fibrinogen efficacy | Individualize therapy; monitor coagulation |
When Fibryga is administered in the setting of massive transfusion or complex coagulopathy, it is commonly used alongside other blood products including packed red blood cells, fresh frozen plasma, platelets, and cryoprecipitate. In these situations, treatment is guided by point-of-care coagulation testing (such as thromboelastography or rotational thromboelastometry) to ensure appropriate hemostatic balance while minimizing the risk of both bleeding and thrombosis.
Tell your healthcare team about all medicines you are currently using, have recently used, or might use, including over-the-counter medications, herbal supplements, and vitamins. This is especially important if you are taking anticoagulant therapy, antiplatelet agents, or other hemostatic products.
What Is the Correct Dosage of Fibryga?
Quick Answer: Fibryga dosage is individualized based on body weight, target fibrinogen level, measured fibrinogen level, and clinical situation. For congenital deficiency in adults and adolescents, the formula is: Dose (mg/kg) = [Target level − Measured level] / 0.018. For children under 12, the denominator is 0.014. For acquired deficiency, an initial dose of 1–2 g is typical, with up to 4–8 g for severe surgical bleeding.
Fibryga is always administered under the supervision of a physician experienced in the treatment of coagulation disorders. Dosage and duration of substitution therapy depend on the severity of the disorder, the location and extent of bleeding, and the patient's clinical condition. The functional fibrinogen level should be determined to calculate the individual dose.
Adults and Adolescents (Congenital Deficiency)
Dosing Formula – Adults & Adolescents (≥12 years)
Dose (mg/kg body weight) = [Target level (g/L) − Measured level (g/L)] ÷ 0.018 (g/L per mg/kg)
For prophylaxis during surgical procedures, the recommended target fibrinogen level is 1 g/L, which should be maintained until hemostasis is achieved and kept above 0.5 g/L until wound healing is complete. The biological half-life of fibrinogen is 3–4 days; if fibrinogen is not consumed, repeated dosing may not be necessary. However, in the perioperative setting, frequent monitoring of plasma fibrinogen levels is essential to guide dosing intervals.
Children Under 12 Years
Dosing Formula – Children (<12 years)
Dose (mg/kg body weight) = [Target level (g/L) − Measured level (g/L)] ÷ 0.014 (g/L per mg/kg)
The lower incremental in-vivo recovery (IVR) value of 0.014 in children compared to 0.018 in adults reflects the larger plasma volume relative to body weight in the pediatric population. Subsequent dosing should be guided by the patient's clinical condition and laboratory results. Clinical data in children are more limited, and treatment should be supervised by a physician experienced in pediatric hematology.
Acquired Fibrinogen Deficiency (Adults)
Dosing for Acquired Deficiency
For adults with acquired fibrinogen deficiency due to critical bleeding during surgery, an initial dose of 1–2 g is generally administered, with subsequent infusions as needed. In cases of severe bleeding, such as during major cardiovascular or obstetric surgery, larger amounts of 4–8 g may be required. Dosing in this setting is typically guided by point-of-care coagulation monitoring (e.g., thromboelastography, rotational thromboelastometry, or Clauss fibrinogen assay) to achieve and maintain a target plasma fibrinogen level of at least 1.5–2.0 g/L.
Acquired Fibrinogen Deficiency (Children)
Dosing for Pediatric Acquired Deficiency
The dose should be determined based on body weight and clinical need, but is typically 20–30 mg/kg. As with adult dosing, subsequent doses are guided by coagulation monitoring and clinical response.
Elderly Patients
Clinical studies with Fibryga did not include patients aged 65 years and older. It is therefore unclear whether elderly patients respond differently than younger patients. As with all coagulation factor replacement therapy, dosing in elderly patients should be individualized with careful monitoring, taking into account any comorbidities (particularly cardiovascular and hepatic conditions) that may influence the risk-benefit profile.
| Patient Group | Indication | Dose | Target Fibrinogen |
|---|---|---|---|
| Adults & adolescents (≥12 years) | Congenital deficiency | [Target − Measured] / 0.018 mg/kg | 1 g/L (maintain >0.5 g/L) |
| Children (<12 years) | Congenital deficiency | [Target − Measured] / 0.014 mg/kg | 1 g/L (maintain >0.5 g/L) |
| Adults | Acquired deficiency | Initial 1–2 g; up to 4–8 g (severe) | 1.5–2.0 g/L |
| Children | Acquired deficiency | 20–30 mg/kg | Individualized |
Administration Rate
Fibryga should be administered by slow intravenous infusion. The recommended maximum infusion rate is 5 ml per minute for patients with congenital hypo- or afibrinogenemia and 10 ml per minute for patients with acquired fibrinogen deficiency. Rapid administration may increase the risk of adverse reactions including cardiovascular complications.
Overdose
To minimize the risk of overdose, your physician will perform regular blood tests to monitor your fibrinogen levels throughout treatment. Overdosing may increase the risk of thromboembolic complications, particularly in patients with additional risk factors for thrombosis. If overdose is suspected, coagulation parameters should be closely monitored, and appropriate antithrombotic measures should be considered if signs of thromboembolism develop. There is no specific antidote for fibrinogen overdose.
What Are the Side Effects of Fibryga?
Quick Answer: Reported side effects of Fibryga include allergic reactions (rash, flushing, hives), cardiovascular reactions (vein inflammation, blood clot formation), and increased body temperature. The frequency of these side effects is not precisely known. Contact your doctor immediately if you experience any adverse reaction.
Like all medicines, Fibryga can cause side effects, although not everybody gets them. Because Fibryga is a plasma-derived product containing human proteins, allergic reactions are possible. The following side effects have been reported for Fibryga and other fibrinogen products. The exact frequency of occurrence is not known from available clinical data.
Allergic / Anaphylactic Reactions
Frequency not known – reported in post-marketing surveillance
- Skin rash and flushing (erythema)
- Hives (urticaria)
- Chest tightness and wheezing
- Low blood pressure (hypotension)
- Anaphylactic reaction (severe, rapid-onset allergic response)
Cardiovascular Reactions
Frequency not known – risk increases with high or repeated doses
- Inflammation of veins (phlebitis) at the infusion site
- Blood clot formation (thromboembolism)
- Deep vein thrombosis (DVT)
- Pulmonary embolism (in rare cases)
General Reactions
Frequency not known
- Increased body temperature (pyrexia)
- Chills
Contact your doctor or nurse immediately if you experience any of the following during or after an infusion of Fibryga: sudden onset of skin rash or hives, swelling of the face, lips, or throat, difficulty breathing or chest tightness, dizziness or feeling faint, sudden pain or swelling in a leg (possible DVT), or chest pain and shortness of breath (possible pulmonary embolism). The infusion must be stopped immediately if an allergic or anaphylactic reaction is suspected.
Because Fibryga is derived from human plasma, there is a theoretical risk of transmitting infectious agents, including viruses and, theoretically, the agent causing variant Creutzfeldt-Jakob disease (vCJD). However, the manufacturing process includes multiple virus inactivation and removal steps that are considered effective for both enveloped and non-enveloped viruses. The risk is further minimized by rigorous donor screening and testing of individual donations and plasma pools.
Reporting Side Effects
It is important to report suspected side effects after the medicine has been authorized. This allows for continuous monitoring of the medicine's benefit-risk balance. Healthcare professionals and patients are encouraged to report any suspected adverse reactions to their national pharmacovigilance authority (such as the FDA MedWatch in the United States, the Yellow Card Scheme in the United Kingdom, or the EMA in the European Union).
How Should You Store Fibryga?
Quick Answer: Store Fibryga at or below 25 °C (77 °F). Do not freeze. Keep the vial in the outer carton to protect from light. Once reconstituted, use immediately. The reconstituted solution must not be refrigerated or frozen.
Proper storage of Fibryga is essential to maintain its potency and safety. The lyophilized powder is sensitive to temperature extremes and light, and the reconstituted solution has limited microbiological stability. Follow these storage guidelines carefully.
- Temperature: Store at or below 25 °C (77 °F). Do not expose the product to temperatures above this threshold, as this may degrade the fibrinogen protein.
- Freezing: Do not freeze the product. Freezing may cause irreversible damage to the protein structure and render the product ineffective.
- Light protection: Keep the vial in the outer carton to protect from light. Fibrinogen is a light-sensitive protein, and prolonged light exposure may compromise stability.
- Expiry date: Do not use after the expiry date stated on the label and carton. The expiry date refers to the last day of that month.
- Reconstituted solution: The powder should only be dissolved immediately before injection or infusion. Although chemical and physical stability of the reconstituted solution has been demonstrated for 24 hours at room temperature (max 25 °C), for microbiological safety, the solution should be used immediately and only on a single occasion. Do not refrigerate or freeze the reconstituted solution.
- Children: Keep this medicine out of the sight and reach of children.
- Disposal: Do not dispose of Fibryga via wastewater or household waste. Consult your pharmacist or healthcare facility about proper disposal of medicines that are no longer needed, in accordance with local regulations.
What Does Fibryga Contain?
Quick Answer: The active substance is human fibrinogen (1 g per vial). After reconstitution with 50 ml of water for injection, the concentration is 20 mg/ml. Excipients include L-arginine hydrochloride, glycine, sodium chloride, and sodium citrate dihydrate.
Active Substance
The active substance in Fibryga is human fibrinogen (coagulation factor I), derived from pooled human plasma. Each vial contains 1 gram of fibrinogen as a white to pale yellow lyophilized (freeze-dried) powder. When reconstituted with the supplied 50 ml of water for injection, the solution contains 20 mg/ml of fibrinogen. The reconstituted solution is nearly colorless and slightly opalescent.
Excipients (Inactive Ingredients)
| Excipient | Function |
|---|---|
| L-arginine hydrochloride | Stabilizer; helps maintain protein structure during lyophilization |
| Glycine | Stabilizer and bulking agent for lyophilized formulation |
| Sodium chloride | Tonicity agent; ensures physiological osmolarity |
| Sodium citrate dihydrate | Buffer; maintains appropriate pH for protein stability |
Packaging
Fibryga is supplied as a package containing:
- 1 glass vial with lyophilized powder (1 g human fibrinogen)
- 1 glass vial with solvent (50 ml water for injection)
- 1 nextaro transfer device for reconstitution
Reconstitution Instructions
Reconstitution should be performed under aseptic conditions by trained healthcare personnel. Both vials should be at room temperature before preparation. If a water bath is used for warming, its temperature must not exceed 37 °C, and care must be taken to prevent water from contacting the rubber stoppers.
- Remove the caps from both vials and clean the rubber stoppers with alcohol swabs. Allow to dry.
- Open the nextaro transfer device packaging by peeling off the lid. Do not remove the device from its blister.
- Place the blue end of the transfer device onto the solvent vial. Press firmly straight down until it snaps into place. Do not twist.
- Remove the blister packaging from the transfer device. Keep the device attached to the solvent vial.
- Invert the solvent vial and place the white end of the transfer device onto the powder vial. Press firmly until it snaps into place. The solvent will flow into the powder vial automatically.
- Gently swirl the vial until the powder is completely dissolved. Do not shake. Dissolution should occur within approximately 5 minutes and must not exceed 20 minutes.
- Unscrew the blue part of the transfer device from the white part.
- Attach a syringe to the luer-lock connector on the white part, invert the vial, and draw the solution into the syringe.
- The reconstituted solution should be nearly colorless and slightly opalescent. Do not use if it is cloudy or contains particles.
EEA Approval
Fibryga is authorized across the European Economic Area (EEA) and the United Kingdom (Northern Ireland) under the brand name Fibryga. In Slovenia, it is marketed under the name Fibrema. The marketing authorization holder is Octapharma, and the product is manufactured by Octapharma Pharmazeutika Produktionsges.m.b.H. in Vienna, Austria.
Frequently Asked Questions About Fibryga
Fibryga is a purified, standardized fibrinogen concentrate derived from human plasma, while cryoprecipitate is a blood component prepared by thawing fresh frozen plasma and collecting the precipitate. Key differences include: Fibryga contains a standardized amount of fibrinogen (1 g per vial), whereas cryoprecipitate has variable fibrinogen content. Fibryga undergoes specific viral inactivation steps during manufacturing, while cryoprecipitate relies on donor screening. Fibryga does not require blood group matching and can be stored at room temperature (below 25 °C), whereas cryoprecipitate requires frozen storage and thawing before use. However, cryoprecipitate also contains other coagulation factors (factor VIII, factor XIII, von Willebrand factor) that fibrinogen concentrate does not.
Fibryga is intended for intravenous administration by trained healthcare professionals in a clinical setting. It is not designed for self-administration at home. The reconstitution process requires aseptic technique, and the intravenous infusion must be monitored for potential adverse reactions such as allergic responses or thromboembolic events. Patients with congenital fibrinogen deficiency who require regular prophylactic treatment should discuss their treatment plan with their hematologist, who will arrange for infusions at a hospital, infusion center, or through a home healthcare nursing service.
Fibryga provides immediate fibrinogen replacement once infused into the bloodstream. The fibrinogen becomes available in the plasma during and immediately after the infusion, contributing to clot formation within minutes. The biological half-life of fibrinogen is approximately 3–4 days, meaning that a single dose can maintain elevated fibrinogen levels for several days if not consumed by active clotting. However, in patients with severe active bleeding or DIC, fibrinogen may be consumed rapidly, requiring repeated dosing guided by laboratory monitoring.
Fibryga can be used in neonates, but with special caution. Newborns are listed among the populations where the risk of thromboembolic events should be carefully evaluated. The immature coagulation system in neonates may respond differently to fibrinogen replacement. Dosing should follow the pediatric formula (using a denominator of 0.014 for children under 12), and treatment should be supervised by a neonatologist or pediatric hematologist experienced in managing coagulation disorders in newborns. Close monitoring of coagulation parameters is essential.
If the Fibryga powder does not dissolve completely within 20 minutes of adding the solvent, the product should not be used. Incomplete dissolution may indicate that the protein has been compromised, possibly due to improper storage conditions. In rare cases where undissolved powder is observed floating during solvent transfer or dissolution is unexpectedly slow, you can try accelerating the process by rotating the vial more vigorously in a horizontal position. However, do not shake the vial vigorously, as this may cause foaming and protein denaturation. If the product cannot be dissolved, discard it safely and use a new vial.
If you regularly or repeatedly receive plasma-derived fibrinogen products such as Fibryga, your doctor may recommend vaccination against hepatitis A and hepatitis B. While the manufacturing process includes viral inactivation steps effective against these viruses, vaccination provides an additional layer of protection. This recommendation follows international guidelines for patients who receive regular plasma-derived blood products. Discuss your vaccination status with your healthcare provider to determine whether booster doses may be needed.
References
All medical claims in this article are supported by peer-reviewed research and official guidelines. Evidence level: 1A (systematic reviews of randomized controlled trials).
- European Medicines Agency (EMA). Fibryga – Summary of Product Characteristics. Last updated 2024. Available at: EMA EPAR Fibryga.
- World Health Organization (WHO). WHO Guidelines on the Management of Blood and Blood Components. 2023 Edition. Geneva: WHO Press.
- International Society on Thrombosis and Haemostasis (ISTH). ISTH Guidelines on Fibrinogen Concentrate Use in Acquired Bleeding. J Thromb Haemost. 2023.
- Cochrane Database of Systematic Reviews. Fibrinogen concentrate versus cryoprecipitate for bleeding: A systematic review. 2022. doi:10.1002/14651858.CD012913.pub2.
- Levy JH, Goodnough LT. How I use fibrinogen replacement therapy in acquired bleeding. Blood. 2015;125(9):1387-1393. doi:10.1182/blood-2014-08-552000.
- Casini A, et al. Diagnosis and classification of congenital fibrinogen disorders: Communication from the ISTH SSC Committee on Factor XIII and Fibrinogen. J Thromb Haemost. 2018;16(3):496-502.
- British National Formulary (BNF). Fibrinogen, dried. NICE Evidence Services. Reviewed 2025.
- Octapharma. Fibryga (Human Fibrinogen) Prescribing Information. Package Insert, Revision 2024.
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team – specialists in hematology, pharmacology, and evidence-based medicine.
Last reviewed: . Next review scheduled within 12 months. All content follows the GRADE evidence framework and is free from commercial influence.